114 related articles for article (PubMed ID: 32485721)
21. Effects of Neoadjuvant Chemoradiotherapy on Pathological TNM Stage and Their Prognostic Significance for Surgically-treated Esophageal Squamous Cell Carcinoma.
Hamai Y; Hihara J; Emi M; Furukawa T; Ibuki Y; Yamakita I; Kurokawa T; Okada M
Anticancer Res; 2017 Oct; 37(10):5639-5646. PubMed ID: 28982881
[TBL] [Abstract][Full Text] [Related]
22. [Long-term outcome of neoadjuvant radiochemotherapy followed by surgery for esophageal cancer: a single institution retrospective study of 102 patients].
Ruffier-Loubière A; Janoray G; Chapet S; de Calan L; Dumont P; Dorval É; Orain I; Calais G
Cancer Radiother; 2015 Aug; 19(5):322-30. PubMed ID: 26215366
[TBL] [Abstract][Full Text] [Related]
23. Retrospective review of patients with locally advanced esophageal cancer treated at the University of Pittsburgh.
Defoe SG; Pennathur A; Flickinger JC; Heron DE; Gibson MK; Luketich JD; Greenberger JS
Am J Clin Oncol; 2011 Dec; 34(6):587-92. PubMed ID: 22101387
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant Chemoradiotherapy for Stage II or III Esophageal Squamous Cell Carcinoma.
Kawai T; Kochi M; Fujii M; Song K; Hagiwara K; Watanabe M; Matsuno Y; Suda H; Yagi R; Takayama T
Anticancer Res; 2017 Jun; 37(6):3301-3306. PubMed ID: 28551681
[TBL] [Abstract][Full Text] [Related]
25. Outcome of neoadjuvant therapies for cancer of the oesophagus or gastro-oesophageal junction based on a national data registry.
Klevebro F; Lindblad M; Johansson J; Lundell L; Nilsson M
Br J Surg; 2016 Dec; 103(13):1864-1873. PubMed ID: 27689845
[TBL] [Abstract][Full Text] [Related]
26. Effect of Extending the Original Eligibility Criteria for the CROSS Neoadjuvant Chemoradiotherapy on Toxicity and Survival in Esophageal Cancer.
de Heer EC; Hulshoff JB; Klerk D; Burgerhof JGM; de Groot DJA; Plukker JTM; Hospers GAP
Ann Surg Oncol; 2017 Jul; 24(7):1811-1820. PubMed ID: 28188501
[TBL] [Abstract][Full Text] [Related]
27. Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus.
Shridhar R; Freilich J; Hoffe SE; Almhanna K; Fulp WJ; Yue B; Karl RC; Meredith K
Ann Surg Oncol; 2014 Nov; 21(12):3744-50. PubMed ID: 24854492
[TBL] [Abstract][Full Text] [Related]
28. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification.
Schneider PM; Baldus SE; Metzger R; Kocher M; Bongartz R; Bollschweiler E; Schaefer H; Thiele J; Dienes HP; Mueller RP; Hoelscher AH
Ann Surg; 2005 Nov; 242(5):684-92. PubMed ID: 16244542
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08).
Ruhstaller T; Thuss-Patience P; Hayoz S; Schacher S; Knorrenschild JR; Schnider A; Plasswilm L; Budach W; Eisterer W; Hawle H; Mariette C; Hess V; Mingrone W; Montemurro M; Girschikofsky M; Schmidt SC; Bitzer M; Bedenne L; Brauchli P; Stahl M; ; ; ;
Ann Oncol; 2018 Jun; 29(6):1386-1393. PubMed ID: 29635438
[TBL] [Abstract][Full Text] [Related]
30. Treatment of clinical T2N0M0 esophageal cancer.
Hardacker TJ; Ceppa D; Okereke I; Rieger KM; Jalal SI; LeBlanc JK; DeWitt JM; Kesler KA; Birdas TJ
Ann Surg Oncol; 2014 Nov; 21(12):3739-43. PubMed ID: 25047477
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of lymphovascular invasion in patients with esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy.
Chen WH; Huang YL; Chao YK; Yeh CJ; Chang HK; Tseng CK; Liu YH
Ann Surg Oncol; 2015 Jan; 22(1):338-43. PubMed ID: 25023545
[TBL] [Abstract][Full Text] [Related]
32. [Salvage surgery in esophageal cancer : Feasibility in patients after definitive radiochemotherapy (> 50 Gy)].
Schmidt T; Sisic L; Sterzing F; Haag GM; Kunzmann R; Grenacher L; Weichert W; Jäger D; Büchler MW; Ott K
Chirurg; 2015 Oct; 86(10):955-62. PubMed ID: 25715974
[TBL] [Abstract][Full Text] [Related]
33. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
Castoro C; Scarpa M; Cagol M; Ruol A; Cavallin F; Alfieri R; Zanchettin G; Rugge M; Ancona E
Ann Surg Oncol; 2011 Dec; 18(13):3743-54. PubMed ID: 21556952
[TBL] [Abstract][Full Text] [Related]
34. Management of Unresectable T4b Esophageal Cancer: Practice Patterns and Outcomes From the National Cancer Data Base.
Cushman TR; Shaaban SG; Moreno AC; Lin C; Verma V
Am J Clin Oncol; 2019 Feb; 42(2):154-159. PubMed ID: 30499838
[TBL] [Abstract][Full Text] [Related]
35. Outcome of Patients Treated Within and Outside a Randomized Clinical Trial on Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: Extrapolation of a Randomized Clinical Trial (CROSS).
Toxopeus E; van der Schaaf M; van Lanschot J; Lagergren J; Lagergren P; van der Gaast A; Wijnhoven B
Ann Surg Oncol; 2018 Aug; 25(8):2441-2448. PubMed ID: 29948420
[TBL] [Abstract][Full Text] [Related]
36. Utility of restaging endoscopic ultrasound after neoadjuvant therapy for esophageal cancer.
Griffin JM; Reed CE; Denlinger CE
Ann Thorac Surg; 2012 Jun; 93(6):1855-9; discussion 1860. PubMed ID: 22516835
[TBL] [Abstract][Full Text] [Related]
37. Time interval between neoadjuvant chemoradiotherapy and surgery for oesophageal or junctional cancer: A nationwide study.
van der Werf LR; Dikken JL; van der Willik EM; van Berge Henegouwen MI; Nieuwenhuijzen GAP; Wijnhoven BPL;
Eur J Cancer; 2018 Mar; 91():76-85. PubMed ID: 29353163
[TBL] [Abstract][Full Text] [Related]
38. Management of locoregional stage esophageal cancer: a single center experience.
Javle MM; Nwogu CE; Donohue KA; Iyer RV; Brady WE; Khemka SV; Smith JL; Demmy TL; Yang GY; Nava HR
Dis Esophagus; 2006; 19(2):78-83. PubMed ID: 16643174
[TBL] [Abstract][Full Text] [Related]
39. Impact of Age and Comorbidity on Choice and Outcome of Two Different Treatment Options for Patients with Potentially Curable Esophageal Cancer.
Faiz Z; van Putten M; Verhoeven RHA; van Sandick JW; Nieuwenhuijzen GAP; van der Sangen MJC; Lemmens VEPP; Wijnhoven BPL; Plukker JTM
Ann Surg Oncol; 2019 Apr; 26(4):986-995. PubMed ID: 30719634
[TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant Therapy Improves Outcomes in Locally Advanced Signet-Ring-Cell Containing Esophagogastric Adenocarcinomas.
Heger U; Sisic L; Nienhüser H; Blank S; Hinz U; Haag GM; Ott K; Ulrich A; Büchler MW; Schmidt T
Ann Surg Oncol; 2018 Aug; 25(8):2418-2427. PubMed ID: 29855828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
